Administrative Core

行政核心

• 批准号: 10237260
• 负责人: Nikhil Wagle
• 金额: $ 57.6万
• 依托单位: BROAD INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10237260
• 关键词: Accountability; Administrator; Adult; Advisory Committees; Advocacy; Age; Behavioral Research; Behavioral Sciences; Benchmarking; Blood; Cancer Biology; Caring; Child; Childhood; Clinical; Clinical Data; Clinical Research; Clinical Trials; Communication; Communities; Computational Biology; Computational Science; Computer Analysis; Consent; Cross Presentation; Dana-Farber Cancer Institute; Data; Data Reporting; Data Science; Databases; Development; Diagnostic Procedure; Elements; Ensure; Expenditure; Failure; Genome; Genomics; Goals; Immunology; Institutes; Leadership; Logistics; Malignant Neoplasms; Medical Records; Molecular; Monitor; Morbidity - disease rate; Participant; Pathology; Patient Recruitments; Patients; Pediatric Oncology; Persons; Population Sciences; Prevention strategy; Reporting; Research; Research Personnel; Research Project Grants; Rural Minority; Saliva; Series; Smooth Muscle; Specimen; Survival Rate; Technology; Time; Tissue Sample; Translational Research; Tumor Tissue; anticancer research; bone; cancer genomics; clinical database; data archive; data de-identification; experience; genomic data; improved; leiomyosarcoma; literacy; meetings; member; novel; osteosarcoma; patient engagement; precision medicine; programs; rare cancer; sarcoma; shared database; targeted treatment; tool; treatment strategy; tumor; tumor DNA; web site

Osteosarcoma (OS) and leiomyosarcoma (LMS) are exceedingly rare cancers, both subtypes of sarcoma, that arise in bone and smooth muscle respectively. There has been a failure to improve survival rates or decrease treatment-related morbidity in OS/LMS due to insufficient characterization of the genomic landscape, resulting in a lack of targeted therapeutic approaches, diagnostic methods, and preventive strategies. There is an urgent need for a large, shared database of clinical and genomic data in OS and LMS. Yet, because of the rarity of these tumor types as well as other challenges in patient recruitment and the genomic characterization of these tumors, to date it has been difficult to generate this data. The overarching goal of this proposal is to engage adult and pediatric participants with OS and LMS as partners to generate a shared database of clinical, genomic, molecular, and patient-reported data. This should accelerate discoveries that drive novel treatment strategies, new clinical trials, and new standards of care. The Count Me In PE-CGS U2C Research Center will leverage our experience in patient engagement, genome characterization, computational analysis, and behavioral research to create and launch two patient-partnered projects to generate this clinicogenomic data. We will build two websites with patients in the OS and LMS communities—the Osteosarcoma Project (OSproject) and the Leiomyosarcoma Project (LMSproject)—and consent 3,000 patients over the course of the study. We will collect medical records, patient-reported data, archival tumor tissue samples, and saliva and blood for genomic analysis. We will generate clinically annotated genomic data from at least 750 tumor specimens, 500 circulating tumor DNA specimens, and corresponding germline specimens and share the de-identified data widely. At the same time, we will study and optimize the approach to patient engagement in cancer research, particularly among rural and minority participants and participants across a range of literacy levels, ages, and stages in development. To accomplish these goals, we will build on a well-established interdisciplinary team from the Broad Institute and Dana-Farber Cancer Institute with members who have pioneered these approaches. Our leadership (Wagle, Janeway) and Units are comprised of experts in patient-partnered cancer research (Wagle, Painter), sarcoma clinical and translational research (Janeway, George, Crompton, Raut), genome characterization, analysis, and clinical interpretation (Gabriel, Getz, Van Allen, Wagle, Janeway), computational biology/data science (Getz, Van Allen, Philippakis), and behavioral science (Mack, Rebbeck). Our Center will uncover the key clinicogenomic features of OS/LMS, integrate them into a single comprehensive database with a goal of accelerating research and improving the lives of these patients. In doing so, we also aim to present a general approach to patient-partnered research that can be disseminated broadly and applied to other tumors types and patient communities.

骨肉瘤（OS）和平滑肌肉瘤（LMS）是极少数癌症，都是肉瘤的亚型， 这是在骨骼和平滑肌敏感的情况下出现的。 由于基因组景观的表征不足，在OS/LMS中与治疗相关的病态相关，导致 缺乏抛弃的治疗方法，诊断方法和预防策略。 需要大量的OS和LMS临床数据数据库。 这些肿瘤类型为患者招募中的挑战和这些肿瘤的基因组表征 迄今为止，肿瘤已经生成该数据的整合目标是参与此数据的差异。 具有OS和LMS的成人和儿科参与者，以生成共享的临床数据库， 基因组，分子和患者报告的数据。 策略，新的临床试验和新的护理标准。 利用我们在患者参与，基因组表征，计算分析和D的经验 行为研究以创建和启动两个临床基因组的患者合作项目 数据。 （Osproject）和平滑肌肉瘤项目（LMSProject） - 在您的过程中同意3,000名患者 研究。 为了基因组分析。 500个循环肿瘤DNA标本和Corpong Germaline标本，并共享识别数据 同时，我们将研究并优化患者参与癌症研究的方法 特别是在各个识字水平的农村和少数民族参与者和参与者中，以及 在发展中的阶段。 Broadite和Dana-Farber癌症研究所与我们的方法开创了 领导力（Wagle，Janeway）和单位是患者合作癌症研究专家的组成（Wagle，Wagle， 画家），肉瘤临床和转化研究（Janeway，George，Crompton，Raut），基因组 表征，分析和临床解释（Gabriel，Getz，Van Allen，Wagle，Janeway）， 计算生物学/数据科学（Getz，Van Allen，Philippakis）和行为科学（Mack，Rebbeck）。 我们的中心将为OS/LMS的关键临床基因组特征，将它们集成到单一的表述中 数据库的目标是加速和改善这些患者的生活。 旨在提出一种可以广泛传播并应用的患者合作研究的一般方法 到其他肿瘤类型和患者社区。